MAP2K7 and thyroid cancer: In thyroid cancer cell lines, where both the PI3K/AKT and RAF/RAS/MEK/ERK pathways are strongly activated due to frequent oncogene mutations, CUDC-907 treatment decreased both pAKT and pERK levels, resulting in growth inhibition in both in vitro and in vivo models [46].